Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma have?
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma has 1,773 citations in the OpenAlex counts ScholarIQ stores.
When was Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma published?
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma has 2021 year in the ScholarIQ index.
What is the open-access status of Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma?
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma has bronze oa status in the ScholarIQ index.
What is the DOI of Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma?
The DOI for Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma is on the source record.
What is the PMID of Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma?
The PMID for Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma is on the source record.
What is the OpenAlex record for Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma?
The OpenAlex for Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma is on the source record.